HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Endorsement Guide Offers Refresher On Social Media Compliance Etiquette

This article was originally published in The Tan Sheet

Executive Summary

FTC’s updated FAQ tackles questions stakeholders have been asking about its Endorsement Guide, including the appropriate way to provide disclosures on social media platforms and the responsibilities of companies using large networks of bloggers and other influencers to promote products.

You may also be interested in...



P&G, U.K. Ad Authority Clash Over YouTube Channel Disclosures

Firm maintains that disclosures visible to U.K. consumers who watch videos on its "Beauty Recommended" YouTube channel - such as "brought to you by Procter & Gamble" – are adequate and go beyond measures taken by competitors. However, the Advertising Standards Authority says the content's "commercial intent" must be clear even before such videos are opened.

FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era

Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.

FTC Testimonial Guide Moves Past "Results Not Typical," Enters Blog Era

The Federal Trade Commission raised the bar on substantiation and disclosure of "typical results" in testimonials and endorsements in advertising, in a revised guide released Oct. 5

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel